Background The burden of invasive pneumococcal disease in young children decreased
dramatically following introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) …

Background Economic evaluations of health interventions pose a particular challenge for
reporting because substantial information must be conveyed to allow scrutiny of study …

Abstract Objectives Pneumococcal conjugate vaccines (PCVs) have significantly reduced
disease burden caused by Streptococcus pneumoniae, a leading cause of childhood …

Abstract Objectives The Centers for Disease Control and Prevention considers carbapenem-
resistant Enterobacteriaceae (CRE) an urgent public health threat; however, its economic …

This study assessed the cost-effectiveness of the 20-valent pneumococcal conjugate
vaccine (PCV20) in Canadian infants aged< 2 years versus the standard of care (SoC), a 13 …

To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7)
program, we conducted a cross-sectional observational study on nasopharyngeal carriage …

Since second generation pneumococcal conjugate vaccines (PCVs) targeting 10 and 13
serotypes became available in 2010, the number of national policy makers considering …

Importance Immunization schedules with pneumococcal conjugate vaccine (PCV) differ
among countries regarding the number of doses, age at vaccinations, and interval between …

Introduction. Cervical cancer is caused by infection with human papillomavirus (HPV).
Several countries have implemented vaccination programs against HPV for teenage girls …

Objective To estimate the cost effectiveness of vaccinating people with high risk conditions
against invasive pneumococcal disease using the 13 valent pneumococcal conjugate …